

4

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 March 2002 (14.03.2002)

PCT

(10) International Publication Number  
**WO 02/19980 A1**

(51) International Patent Classification<sup>7</sup>: A61K 7/48, 31/70

Couperin, F-94440 Santeny (FR). GESZTESI, Jean-Luc [BR/BR]; Rua General Jardim, 840, 5. andar, São Paulo, SP (BR).

(21) International Application Number: PCT/BR01/00115

(22) International Filing Date:  
11 September 2001 (11.09.2001)

(74) Agent: DANNEMANN, SIEMSEN, BIGLER & IPANEMA MOREIRA; Caixa Postal 2142, Rua Marques de Olinda, 70, Botafogo, CEP-22251-040 Rio de Janeiro, RJ (BR).

(25) Filing Language: English

(26) Publication Language: English

(81) Designated States (*national*): CA, JP, MX, US.

(30) Priority Data:  
00/11546 11 September 2000 (11.09.2000) FR  
P1 0100957-5 13 March 2001 (13.03.2001) BR

(84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

(71) Applicant (*for all designated States except US*): INDÚSTRIA E COMÉRCIO DE COSMÉTICOS NATURA LTDA. [BR/BR]; Rodovia Anhanguera s/n - Km 30,5, CEP-0007750-000 Cajamar, SP (BR).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): LADISLAS, Robert [FR/FR]; 7, rue Jean-Baptiste Lully, F-94440 Santeny (FR). ROBERT, Alexander, Michel [FR/FR]; 41, rue François

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 02/19980 A1

(54) Title: COMPOSITION OF VITAMIN C AND/OR VITAMIN A

(57) Abstract: The present invention relates to a new cosmetic or pharmaceutical composition characterized in that it comprises at least one vitamin component chosen from the group consisting of vitamin C and its derivatives, vitamin A (or retinol) and its derivatives, and mixtures of these components, in association with at least one fucose component chosen from the group consisting of fucose, polysaccharides and oligosaccharides that contain fucose, consisting of fucose, polysaccharides and oligosaccharides that contain fucose, and mixtures of these components, as well as at least one acceptable excipient. This composition enables one to reduce significantly, by means of a real synergy effect, the toxic effect of the vitamin component and, therefore, to use in the composition contents of the vitamin component higher or equal to the contents of the products that already exist on the market, without any risk for the user.

## COMPOSITION OF VITAMIN C AND/OR VITAMIN A

5           The present invention relates to a new cosmetic or pharmaceutical composition that comprises an association of vitamin C and/or vitamin A with a fucose component, and to the use of this association specially in products of topical application, for which an activity on the epithelial or conjunctive tissue is sought, especially anti-aging products such as pharmaceutical or  
10   veterinary products and, more specially, in cosmetic products.

          Collagen, the largest constituent of the dermis, undergoes, according to earlier papers (BRANCHET et al, *Arch. Gerontol. Geriatr.*, 1991, 13:1-14), a quantitative decrease with the aging. The regulation of its biosynthesis is therefore a very important step to consider in fighting against  
15   skin aging.

          If it is well known that ascorbic acid (or "vitamin C") and its salts (specially sodium) have stimulating effects on the biosynthesis of collagen, on the other hand it has been possible to point out its cytotoxic effect starting from a concentration of about 0.01% by weight.

20           The activation effect of biosynthesis of collagen, which is quite favorable, can be observed in clichés of electronic microscopy, by a great expansion of the vesicles of the rugose endoplasmic reticulum, full of neosynthesized proteins.

          The cytotoxic effect, which is unfavorable and can be observed in  
25   millimolar concentrations of ascorbate (about 2.5 mM), manifests itself by displacing the cells of its substrate, by decelerating their proliferation and the cellular feasibility, and then by cellular death.

          On the other hand, retinol (or "vitamin A"), as well as other retinoids such as retinyl palmitate, are compounds appreciated especially in the  
30   domain of cosmetic products for its biologic activities that are favorable mainly in fighting against skin aging. These activities disclosed by topical utilization of vitamin A and its derivatives are appreciated, for instance, in the

article by Wade Cheng, PhD and Shirley De Petris, "Vitamin A Complex", Skin Inc, March/April, 1998.

However, the use of pure vitamin A or one of its derivatives has the drawback of so high toxicity, that one should limit the dosage or adding components, specially to minimize the discomfort of irritation of the skin that results therefrom.

It was specially pointed out that retinol introduces inhibition of cellular proliferation in fibroblasts in conventional culture (Lacroix A , Anderson G. D.L., Lippman M.E., "Retinoids and cultured human fibroblasts", Exp Cell Res, 1980; 130: 339-344; Harper R.A., Burgoon T., "Differential effects of retinoic acid on the growth of normal fibroblast-like cells in vitro from human, swine and rabbit skin", Cell Biol Int Rep, 1982, 6: 163-170; or else Stumpenhause G., Hein R., Kulozik M., Mauch C., Bryce G.F., Oono T., Kieg Th., "The influence of retinoids on fibroblasts functions", in Saurat JH ed., Retinoids: 10 years On, 1991, pp. 139-150 Karger, Basel). This is a real toxic effect of retinol on fibroblasts.

Vitamins C and A and the salts and derivatives thereof being vitamin components often present mainly in cosmetic products, especially anti-aging cosmetic products, it was therefore quite desirable to overcome the above-cited drawbacks, so as to increase the contents and, consequently, the favorable effects of these components, while reducing their toxic effects at the same time.

It has now been found, in an absolutely surprising and unexpected way, that the association of fucose or a polysaccharide or oligosaccharide containing fucose with vitamin C and/or vitamin A enables one to reduce significantly the toxic effects of these vitamins, with a real synergistic effect.

Thus, the present invention has the objective of providing a cosmetic or pharmaceutical composition characterized by comprising at least one vitamin component chosen from the group consisting of vitamin C and its derivatives, vitamin A (or retinol) and its derivatives, and mixtures thereof, in association with at least one fucose component chosen from the group consisting of fucose, polysaccharides and oligosaccharides containing fucose,

and mixtures of these components, as well as at least one cosmetically or pharmaceutically acceptable excipient.

By "derivatives of vitamin C" one understands, especially according to the invention, salts such as sodium ascorbate and esters such as ascorbyl phosphate or ascorbyl palmitate.

The term "retinol" (or vitamin A) should be understood as including hydrogenated and non-hydrogenated isomers such as 9-cis-retinol and didehydroretinol.

By "derivatives of vitamin A" one understands, especially according to the invention, other retinoids than retinol, especially esters obtained with retinol and acetic acid, propionic acid, palmitic acid or stearic acid and, more specially, retinoic acid, retinaldehyde (or retinal) and retinyl palmitate.

The term "retinaldehyde" should be understood as including the 4 stereoisomeric forms trans, 13-cis, 11-cis and 9-cis.

The monosaccharide fucose is a deoxyhexose close to galactose, of which it has the stereochemical conformation. However, the structure of fucose essentially differs from the structure of galactose in that the carbon-6 atom has a methyl group ( $-\text{CH}_3$ ) and not a primary alcohol group ( $-\text{CH}_2\text{OH}$ ). In fact, this methyl group imparts an interesting partial hydrophobic nature to the molecule of fucose, which is compensated by other hydroxyl groups in the four other carbon atoms present.

The monosaccharide fucose usable in the composition according to the invention may be L-fucose, D-fucose or one of their mixtures. L-fucose and D-fucose may each be in the form of alpha, beta or a mixture of these forms. These products are specially commercialized by SIGMA.

Fucose appears early in the course of phylogenesis, polysaccharides of certain algae and of fungi contain fucose in relatively large quantity, either alone or in combination with other chemical compounds. On the other hand, fucose is widespread in the vegetable kingdom and certain bacteria also synthesize it. Fucose may also appear in the sulfated form, as in fucanes.

Thus, by the expression "polysaccharides and oligosaccharides

containing fucose" one understands any polysaccharide or oligosaccharide that comprises at least one fucose unit, including the sulfated polysaccharides and oligosaccharides "fucanes".

Fucanes are sulfated polysaccharides that form a constituent part of the cellular walls of the stalks of brown algae (Feoficeas). They are also present in certain marine animals such as sea-urchin and sea-cucumber. Raw fucane, also called fucoidanes, obtained by acidic extraction from the cellular walls of the stalks of brown algae, is constituted by a heterogeneous population of molecules, which comprises mainly polymers of sulfated L-fucose of high average molar mass (from 100,000 to 800,000 g/mol). Preparations of fucanes of lower average molar mass (lower than 20,000 - 10,000 g/mol) have been obtained, for instance, by controlled hydrolysis of fucane of high molar mass, as described in EP-0 403,377, or by radical depolymerization, as described in WO 97/08206. One can also cite especially the product called "Fucoidane" commercialized by SIGMA.

Among the polysaccharides and oligosaccharides that contain fucose usable in the composition according to the invention other than fucanes, one can cite especially those commercialized by Solabia, such as the polysaccharide "Fucogel 1000". Application WO 96/23057 describes the process of preparing this polysaccharide, which comprises the repetition motif fucose-galactose-galacturonic acid.

On the other hand, a new mixture of oligosaccharides containing fucones, hereinafter called "Mixture of oligofucoses" specially suitable for the present invention, is found.

This is a mixture of non-sulfated fucose-based oligosaccharides characterized in that it comprises oligosaccharides of less than 13 saccharide units, which comprise at least one fucose unit in a non-reducing end position, and that it can be obtained by means of a process that comprises at least one step of degradation of a polysaccharide from a microorganism of the gender *Klebsiella pneumoniae subsp. pneumoniae*.

By "non-sulfated fucose-based oligosaccharide" one understands, according to the invention and in accordance with the general

knowledge of those skilled in the art, an oligosaccharide that contains at least one unit of saccharide fucose and that has not sulfate group  $-O(SO_3)^-$ . Fuca-  
nes are especially excluded from this definition.

By "oligosaccharide that comprise at least one unit of fucose in a  
5 non-reducing end position" one understands, according to the invention and  
in accordance with the general knowledge of those skilled in the art, an oligo-  
saccharide that contains at least one unit of saccharide fucose in an end po-  
sition of the chain of oligosaccharides, this fucose unit being linked to the  
next saccharide unit of the rest of the oligosaccharide by an acetal-type  
10 linkage.

The numbers of saccharide units may be measured with the help  
of techniques well known to a person skilled in the art, especially using for  
this purpose the HPLC chromatography, as described in the examples given  
below.

15 Preferably, the Mixture of oligofucoses comprise, based on the  
total weight of the mixture, at least 15% by weight, and preferably from 20 to  
50% by weight of oligosaccharides of less than 13 saccharide units, which  
comprise at least one fucose unit in a non-reducing end position.

More specially, the Mixture of oligofucoses is characterized by  
20 comprising, on the other hand, based on the total weight of the mixture, from  
25 to 45% by weight of oligosaccharides that contain from 13 to 24 sacchari-  
de unit comprising at least one fucose unit in a non-reducing end position.

Still more specially, the Mixture of oligofucoses is characterized  
in that it comprises, on the other hand, based on the total weight of the mixtu-  
25 re, from 15 to 35% by weight of oligosaccharides of more than 54 saccharide  
units comprising at least one fucose unit in a non-reducing end position.

Since the Mixture of oligofucoses can be obtained by a process  
that comprises at least one step of degradation of a polysaccharide from a  
microorganism of the gender *Klebsiella pneumoniae subsp. pneumoniae*, the  
30 oligosaccharides preferably comprise, at least in part, the repetition motif fu-  
cose-galactose-galacturonic acid.

Especially, the Mixture of oligofucoses is susceptible of being

obtained by the process that comprises the steps of:

a) causing the microorganism of the gender *Klebsiella pneumoniae subsp. pneumoniae* to grow in an aqueous nutritive medium by aerobic fermentation of an assimilable source of glucide;

5           b) recovering the polysaccharide formed from the fermentation must;

c) subjecting the polysaccharide to a moderate hydrolysis;

d) subjecting the hydrolysis product of the step c) to an enzymatic hydrolysis; and

10           e) deactivating the enzyme and then recovering the Mixture of oligofucoses thus obtained.

More specially, these steps a) to e) may be described as follows.

Step a)

15           One uses preferably the microorganism *Klebsiella pneumoniae subsp. pneumoniae*, which is a microorganism deposited in the National Collection of Cultures of Microorganisms under number I-1507, or a mutant thereof. On the other hand, this microorganism is described in detail in application WO 96/23057.

20           The aqueous nutritive medium may be any aqueous medium known to a person skilled in the art, which contains sources of carbon, nitrogen and mineral salts, as described in application WO 96/23057.

          One may conduct the fermentation at temperatures on the order of from 25 to 35 °C, at a pH of from about 6.0 to 7.5, in conditions of aeration and stirring, during periods of time ranging from 2 to 4 days.

25           The fermentation may be effected in a classic fermenter, by inoculating previously sterilized nutritive medium, for instance, by heating up to a temperature on the order of 120°C or by sterilizing filtration.

Step b)

30           At the end of the period of fermentation, one recovers the fermentation must, from which a fucose-rich polysaccharide is isolated in the following way.

The fermentation must is subjected to a heat treatment at a tem-

perature specially ranging from about 100 to about 130°C, preferably from about 115 to about 125°C, for a period of time ranging from 30 minutes to about 2 hours and, preferably, from about 40 minutes to about 1 hour, and at a pH specially ranging from about 2 to about 5.5 and, preferably, from about 3 to about 5.5.

The product of the heat treatment is filtered according to classic means, such as press filters with plates.

In this way, one obtains a limpid, viscous polysaccharide, free from any cell.

Then one carries out precipitation in an alcohol solvent, preferably an alcohol solvent chosen from ethanol, isopropanol and mixtures thereof. One specially uses from about 1 to about 3.0 volume of solvent to 1 volume of polysaccharide and, preferably, from about 1.3 to about 2.0 volume of solvent to 1 volume of polysaccharide.

Then a drying is carried out under vacuum, at a temperature specially ranging from about 20 to about 60°C and, preferably, from about 30 to about 50°C, until a powder is obtained.

Steps c) and d): hydrolysis of the polysaccharide

This is an essential combination of steps. Indeed, one has found, in a surprising and unexpected way, that the combination of a step of moderate hydrolysis, preferably by irradiation with gamma rays and/or by protolysis, with an enzymatic hydrolysis step, enables one to obtain advantageously a sufficient global output of hydrolysis, close to that of a classic hydrolysis, such as an acidic hydrolysis, but with the advantage of specific cuts of an enzymatic hydrolysis. In particular, an acidic classical hydrolysis does not enable one to obtain the mixture of specific oligofucoses, as it leads to the obtention of statistic, redhibitory cuts, as to the random nature. On the other hand, the compounds resulting from a classic acidic hydrolysis prove to be biologically inactive.

Step c): moderate hydrolysis of the polysaccharide

Moderate hydrolysis is carried out by a treatment with gamma rays, a protolysis treatment or by these two successive treatments. Prefera-



bly, one successively carries out a treatment with gamma rays and then a protolysis treatment.

The treatment with gamma rays proved to cause a sensible drop in viscosity by a limited degradation, attributable to the action of free radicals. It may be carried out with irradiation means known to those skilled in the art.

This treatment by gamma rays, which are very penetrating rays, presents, in addition, the advantage of sterilizing the polysaccharide, killing the germs present, which could induce inflammation or even cause granuloma. In this way, one prevents a bacterial attach, without having to add to the medium any antiseptic products that could interfere in an undesirable way with the biologic activities of the end product.

The polysaccharide powder obtained in step b), possibly irradiated with gamma rays, may therefore, equally, be subjected to a protolysis treatment. For this purpose, it is placed in an aqueous solution, specially at the proportion of from 1 to 20% by weight and, preferably, from 2 to 10% by weight, with respect to the total weight of the aqueous solution.

The aqueous solution is subjected to a heat treatment, that is to say, a heating up to a temperature specially ranging from about 75 to about 120°C and, preferably, from about 90 to about 100° C, for a period of time ranging from 1 to 6 hours, in the presence of a proton-generating resin, such as those commercialized and well known to a person skilled in the art, that is to say, a resin generating protons that bring about a cut of the glycosidic linkages with fixation of a water molecule.

Step d): enzymatic hydrolysis

One introduces an acidic buffer such as a citric acidic buffer (4.15 g/kg)- disodium hydrogenophosphate (about 10.75 g/kg) in the hydrolysate obtained in step b). One regulates the temperature of the solution specially to a temperature ranging from about 25 to about 45°C and, preferably from about 30 to about 40°C.

One introduces an enzymatic preparation comprising at least one endofucosidase preferably Fermizyme HCP such as commercialized by Gist

Brocades, according to contents specially from about 2 to about 20% by weight and, preferably, from about 5 to about 15% by weight, with respect to the initial weight of polysaccharide powder utilized.

5 The thus obtained mixture is maintained under stirring for a period of time ranging from about 8 to about 24 hours and, preferably, from about 10 to about 20 hours, at a temperature specially ranging from about 25 to about 45°C and, preferably, from about 30 to about 40°C, the pH being regulated at 6 by the presence of the buffer mixture.

Step e)

10 The hydrolysis product obtained after the step d) is filtered according to classical means such as a press filter with plates.

The collected solution is then heat-treated at a temperature specially ranging from about 75 to about 120°C and, preferably, from about 90 to about 105°C, for a period of time specially ranging from about 10 to about 45  
15 minutes and, preferably from about 20 to about 35 minutes, in order to deactivate the enzyme and, more particularly, the fucosidase activity of this specific enzyme.

One lets it cool down to a temperature specially ranging from about 20 to about 40°C.

20 While it is cooling, preservatives may be added to the solution.

One then filters the whole under sterile conditions, and then the packaging is carried out.

The thus obtained mixture of oligofucoses may be characterized with the aid of techniques well known to those skilled in the art, specially  
25 HPCL, chromatography on the thin layer and other methods and chemical dosages.

In this way, one can find out that the oligosaccharides of the mixture are such that fucose is mainly at the end of the chain in a non-reducing end position.

30 The favorable effects of the composition according to the invention manifest themselves in minor concentrations of fucose components, preferably at a concentration ranging from about 0.001 to about 20% by weight,

and more preferably from about 0.01 to 10% by weight, the concentration in vitamin component ranging preferably from about 0.001 to about 90% by weight, and more preferably from about 0.01 to about 10% by weight, based on the total weight of the composition.

5 By choosing adequately the respective concentrations of the vitamin component and of the fucose component, it is possible to reduce significantly, and even to suppress the toxic effect of the vitamin component and, therefore, to use, in the composition according to the invention, contents of vitamin component higher or equal to the contents of product that already  
10 exist in the commerce, without any risk for the user.

Preferably, the weight ratio of vitamin component:fucose component ranges from about 800:1 to about 1:2, and more preferably from about 600:1 to about 1:1.

The cosmetically or pharmaceutically acceptable excipient may  
15 be any one from those known to a person skilled in the art for the purpose of obtaining a composition according to the invention in the form of a cream, a lotion, a gel, a salve, etc., possibly in the form of an emulsion, having, in addition, other components known to a person skilled in the art, to improve, modify or stabilize the composition from a cosmetic or pharmaceutical point  
20 of view.

The expression "pharmaceutically acceptable excipient" embraces excipients adapted for a veterinary use of the composition, according to the invention.

The composition according to the invention may, in particular,  
25 contain other additives and aids to the formulation, such as antioxidant agents for fighting free radicals. One can cite specially pure vitamin E or di-alpha-tocopherol and its derivatives, and 2,6-di-tert-butyl-p-cresol (BHT).

According to a special mode of carrying out the present invention, the composition comprises, on the other hand, a vector, such as microspheres that contain especially the vitamin component, as for example, the  
30 "Talaspheres" described in US-5,395,620 or in patent application PI 9706994-7 of the same applicant.

The composition according to the invention may comprise, for instance, a plurality of dispersed microspheres, which comprise a first vitamin-C component in a first group of microspheres and a second vitamin-A component in a second group of microspheres, the fucose component being  
5 outside the microspheres, in the rest of the composition. Naturally, a variant of this mode of carrying out the invention may consist in that the vitamin-C and/or vitamin-A component is comprised in a single group of microspheres.

Advantageously, the composition according to the invention may  
10 further comprise, in particular, at least one cosmetically or pharmaceutically acceptable additive chosen from the group consisting of the agents structuring the skin (such as squalane and sphingolipides), the moistening agents (such as glycerin and hydroxy prosilan C), the emollients (such as butylene glycol and cetyl lactate, the silicones (such as cyclomethicone), the sun protection agents (such as Parsol 1789 and Eusolex 6300), the emulsifiers (specially Carbopol 1342 associated to triethanolamine and soybean lecithin), the  
15 thickeners (notably xanthan gum), the scavengers (specially EDTA), the antioxidants (such as BHT described above), the fragrances, the preservatives and mixtures thereof.

20 Of course, the operational conditions for preparing the composition according to the invention are part of the general knowledge of those skilled in the art.

The present invention has further the objective of using, in a cosmetic or pharmaceutical composition, of at least one vitamin component  
25 such as defined above, in association with at least one fucose component as defined above, to reduce the toxic effects of the vitamin component.

Preferably, one uses a weight ratio of vitamin component:fucose component ranging from about 800:1 to about 1:2, and more preferably from about 600:1 to about 1:1.

30 Finally, the present invention further has the objective of providing a method for cosmetic or pharmaceutical treatment of the skin, characterized in that one applies to the skin a cosmetic or pharmaceutical composition.

tion as defined above.

Especially, the present invention has the objective of providing a cosmetic treatment of the skin, characterized in that one applies to the skin a cosmetic composition as described above.

5           The examples given below illustrate a real synergy between fucose, the oligosaccharides with fucose with the retinol and the ascorbate, and justify their association specially in a cosmetological "anti-aging" preparation.

10           The following examples, however, are only intended to illustrate the present invention and should not at all be taken as limiting the scope of the invention.

15           Figure 1 is a histogram that brings the results presented in example 4.b.1, in terms of percentage of effectiveness of fucose and of the Mixture of oligofucoses-1 for stimulating the synthesis of collagen by the fibroblasts.

          Figure 2 is a histogram that brings the results presented in example 4.b.2, in terms of percentage of effectiveness of fucose and of the Mixture of oligofucoses-1 for stimulating the biosynthesis of collagen by the fibroblasts in the presence of sodium ascorbate.

20           Figure 3 is a histogram that brings the results presented in example 4.b.3, in terms of percentage of effectiveness of fucose and of the Mixture of oligofucoses-1 for stimulating the synthesis of collagen in the presence of retinol.

#### **Example 1: preparation of a Mixture of oligofucoses**

##### 25           a)       **Fermentation**

          One uses the microorganism *Klebsiella pneumoniae subsp. pneumoniae*, which is a microorganism deposited in the National Collection of Microorganisms under No. I-15097. The nutritive medium and other conditions of the fermentation are as follows.

##### 30           Preparation of the inoculums

Culture medium:

Neosorb® 70-07 (sorbitol contents: 70% M.S.;

sold by ROQUETTE FRERES, Lille / France): 17.90 g/l (that is, 12.5 g/l of sorbitol)

Peptone Biokar 104003 (protein hydrolysate, sold by SOLALBIA-BIOKAR, Pantin, France): 4.50 g/l

5 Yeast extract: 0.05 g/l

$\text{KH}_2\text{PO}_4$ : 1.50 g/l

$\text{K}_2\text{HPO}_4$ : 4.50 g/l

$\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ : 0.20 g/l

10 Pluronic® PE 61000 (antifoaming agent, sold by BASF, D-6700 Ludwigshafen, Alemanha): 0.50 g/l

Placing in solution into water

Culture condition:

Sterilization at 121°C for 30 minutes

Culture temperature: 30°C

15 Inoculation rate: 5 - 10%

Aeration: 1 VVM

pH not regulated (pH of about 7.00)

Duration of culture: 24 hours

Production medium

20 Culture medium:

Neosorb® 70-07: 54.00 g/l (that is, 38 g/l of sorbitol)

Peptone Biokar 104003: 4.50 g/l

Yeast extract: 0.05 g/l

$\text{KH}_2\text{PO}_4$ : 1.50 g/l

25  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ : 0.20 g/l

Pluronic® PE 61000: 0.50 g/l

Placing in solution into water

Culture conditions (fermenter Chemap, which has a useful volume of 350 liters):

30 Sterilization at 120°C for 45 minutes

Culture temperature: 30°C

Inoculation rate: about 5%

Stirring: 300 rpm (Rushton-type stirrer)

Aeration: 1 VVM

pH regulated at 7.0 by NaOH 7N

Pressure: 100 - 200 mbars

5 Duration of culture: 60 - 65 hours

Average values achieved in production:

Viscosity at the end of the cycle: 40000 MPa.s (Viscosimeters Brookfield DV-II+model LV, movable body SP 31, chamber SC4-34/13R, 30°C)

10 Concentration of the polysaccharide produced in the medium, calculated in L-fucose: 2 g/l (Methods: Dische and Shettles)

Sorbitol consumed: >35 g/l (in sorbitol)


NaOH at 20% by weight consumed: 15 liters/m<sup>3</sup>

15 Start of regulation of the pH: 16 - 17 hours after inoculation of the fermenter

Final dry extract of the fermentation medium: ~20 g/l

#### b) Recovery of the formed polysaccharide

One subjects the fermentation must to a heat treatment at a temperature of 120° C for 45 minutes and with a pH of 5.5. The product of the heat treatment is filtered with the help of a press filter with Seitz-type plates. In this way, one obtains a limpid, viscous polysaccharide, free from any cell. Then one carries out a precipitation in 1.5 volume of ethanol to 1 volume of polysaccharide. Then a drying is carried out under vacuum at a temperature of 25°C until a powder is obtained. Considering the microorganism used, this polysaccharide is composed of repetitive trisaccharide units of fucose - galactose - galacturonic acid, and thus it presents the following structure:



**c) Moderate hydrolysis of the polysaccharide**

The polysaccharide powder is placed in aqueous solution at the proportion of 5% by weight, based on the total weight of the aqueous solution. The aqueous solution is subjected to a heat treatment, that is to say, heating up to 100° C, for 3 hours, in the presence of a proton-generating resin.

**d) Enzymatic hydrolysis**

One introduces the buffer mixture of citric acid (4.15 g/kg)-disodium hydrogenphosphate (about 10.75 g/kg) into the hydrolysate. The temperature of the solution is regulated at 37°C. One introduces the enzymatic preparation Fermizyme HCP, as commercialized by Gist Brocades, according to contents of 10% by weight, based on the initial weight of polysaccharide used, that is to say, 0.05% by weight with respect to the total mass of the aqueous solution after placing the powder into water, as described above for the moderate hydrolysis by protolysis.

The thus obtained mixture is kept under stirring for 15 hours at a temperature of 37°C, the pH being regulated at 6 by the presence of the buffer mixture.

**e) Deactivation of the enzyme and recovery of the mixture of oligosaccharides**

The product of hydrolysis is filtered with a press filter with Seitz-type plates. The solution collected is then heat-treated at 100°C, for 30 minutes, to deactivate the enzyme. One lets it cool at a temperature of 25°C. When it is cooling, the preservatives phenoxy ethanol (1% by weight) and phenonipe (0.3% by weight) are added to the solution. Then the whole is filtered in sterile conditions.

The thus obtained mixture of oligosaccharides is called "Mixture of oligofucoses-1".

**Example 2: HPLC characterization of the Mixture of oligofucoses-1**

The fractionation of the Mixture of oligofucoses-1 obtained in Example 1 was carried out with the objective of determining the proportion of



oligo- and of polysaccharides in its composition.

**a) Fractionation by Preparative Exclusion Chromatography on column "XK 50/60 Superdex 75 prepgrade"**

One passes 50 ml of the Mixture oligofucoses-1 concentrated at 50 mg/ml, on a preparative column "XK 50/60 Superdex 75 prepgrade" (exclusion chromatography) and collects 95 fractions, then passed in HPLC.

**Table 1: Technical informations referring to the preparative column XK 50/60 Superdex 75 prepgrade**

Packing	Superdex 75 prepgrade (34 $\mu$ m)
Column size	Height: 50 cm Diameter: 60 mm
Column type	XK 50/60
Usable interval of fractionation	$5 \times 10^2$ Da- $3 \times 10^4$ Da
Injected sample	50 ml of the mixture of oligofucoses-1 at concentration of 50 mg/ml (total: 2.50 g)
Elution Speed	1 ml/minute
Number of collected fractions	95 fractions of 12.5 ml each
Movable phase	PBS

After fractionation the Mixture of oligofucoses-1 on the column "XK 50/60 Superdex 75 prepgrade", 95 fractions are collected, 45 of which contain osides.

**b) Characterization of the fractions obtained by HPLC (exclusion chromatography), ultrahydrogel 120 and ultrahydrogel 250 columns**

The objective of this second part of the study was to pass all the 95 fractions of the mixture of oligofucoses-1 on a HPLC exclusion column (Ultrahydrogel 120 and 250 columns), in order to analyze the molecular weights and the concentration of the components of these fractions.

For this study one has worked with a Waters HPLC system, the description of which follows.

**Table 2: technical characteristics of the HPLC chromatogra-**

phy system used.

Apparatus	HPLC Waters 600
Columns	Ultrasorb 120 (pore size: 120 Å) and Ultrasorb 250 (pore size: 250 Å) from Waters. Size: 7.8 mm x 300 mm, containing the gel of hydroxylated polymethacrylate
Injected samples	20 µl per automatic injector
Elution	0.10 M NaNO <sub>3</sub>
Time of elution	50 minutes/samples
Elution speed	0.5 ml/minute
Detection	By measuring the refraction index with a Waters 410 refractometer

**Table 3: standards of molecular weights of polyethylene glycol (Fluka) used for the HPLC exclusion chromatography**

Molecular weight	Time of elution (minutes)
400	37.892
600	36.026
1000	33.940
2000	31.154
4000	28.896
6000	27.868
8000	26.946
12000	26.192
20000	25.308
35000	24.216

### c) Results

5

The molecular weights of the components of the studied fractions were calculated, by using the following equation, obtained with the standards of molecular weights of Fluka, described in Table 3:

$$\text{Molecular weight of the components} = 55290000 \cdot 10^{(-0.13942 \cdot X)}$$

x)

10

$$R^2 = 0.982$$

X = time of elution (minutes)

The first fraction containing components of the Mixture of oli-

gofucoses-1 is fraction No. 44 and the last one is fraction No. 89, which means that the same component of the less elevated molecular weight is obtained after 89 fractions collected (after an elution of  $89 \times 12.5 \text{ ml} = 1112.5 \text{ ml}$ ). The fractions collected contain mono-, oligo- and polysaccharides of 184Da (mixture of monosaccharides) up to about 21 kDa. Therefore, this fraction contains polysaccharides formed by an average of 117 monosaccharide units or of 39 trisaccharide units.

Most of the fractions, with the exception of fractions No. 77, 78, 79, 81, 82, 83, 84, 85, and 86, contain a single saccharide peak (separation limited by the sensitivity of the separation method applied).

The approximate concentration of the different fractions may be determined by using an appraisal range of fucose standard at growing concentrations. This kind of "mono-compositional" standard range could be used thanks to the detection system (measure of the refraction index with a refractometer). According to these results, a solution of  $1 \mu\text{g/ml}$  of fucose gives, on an average, a surface peak of 29409 (arbitrary units of the system). Knowing the surfaces of the peaks analyzed, it was possible to calculate their apparent concentrations.

The achieved results show that the Mixture of oligofucoses-1 contains approximately 26% of small osides (up to 2 kDa, about 4 trisaccharide units), about 36% of oligosaccharides (up to 4 kDa, 8 trisaccharide units) and about 23% of polysaccharides of molecular weight higher than 10 kDa (18 trisaccharide units).

Taking into consideration the microorganism and the specific enzyme (endo-fucosidase) used for preparing the Mixture of oligofucose-1, it follows that the oligosaccharides of the mixture contain a fucose unit in non-reducing end position.

**Example 3: action of the association of the Mixture of oligofucoses-1 with sodium ascorbate and/or retinol on the fibroblasts of human skin**

The Mixture of oligofucoses-1 as prepared in example 1 is tested in concentrations of  $1 \mu\text{g/ml}$  and  $10 \mu\text{g/ml}$ , both alone and in the simultaneous

presence of 375 µg/ml of sodium ascorbate and/or 20 µg/ml of retinol.

**a) Methodology**

**a .1) Study of the cellular proliferation**

The fibroblasts of human skin used in this study come from the  
5 removal of skin from a 20 years old woman (28<sup>th</sup> passing). The cells were  
cultivated on 12-well plates, in a DMEM culture medium with 10% of fetal calf  
serum (SVF), 1% of antibiotics and of antifungus (PSF), and 1 µCi/ml of [<sup>3</sup>H]-  
timidine (ICN) for 72 hours in the presence of the products to be tested at  
final concentrations of 1 µg/ml and 10 µg/ml.

10 After 72 hours of culture in stove (5% (v/v) CO<sub>2</sub>, 95% (v/v) air)  
at 37° C in the presence of the tested products, the cells were washed four  
times with PBS, then the cellular carpet was detached for 0.05% of tripsin.  
Three ml of scintillation liquid were then added per sample, then the  
radioactivity incorporated in the cells is read in a computer with scinti-  
15 llation.

**a .2.) Synergy with retinol**

One incubated the cells with 20 µg/ml of retinol (69.72 µM). Reti-  
nol induces, in the absence of the oligosaccharides, a decrease in the cellu-  
lar proliferation of about 45% (table 2 below). Two concentrations were tes-  
20 ted: 1 µg/ml and 10 µg/ml.

**a .3) Study of synergy with Na ascorbate**

One incubated the cells with 375 µg/ml of Na ascorbate (1.875  
mM). Vitamin C induces, in the absence of fucose or of the Mixture of oligo-  
fucoses-1, a decrease in the cellular proliferation of about 60% (table 3 be-  
25 low). Two concentrations were tested: 1 µg/ml and 10 µg/ml.

**a .4) Synergy with Na ascorbate and retinol**

The cells were simultaneously incubated with 375 µg/ml of Na  
ascorbate and 20 µg/ml of retinol. This combination produces a great inhibiti-  
on of the proliferation, partly obtained by the tested products.

30 **b.) Results**

**b.1) Action on the cellular proliferation**

72-hour incubation of the fibroblasts with the Mixture of oligofo-

coses-1 stimulated the cellular proliferation in comparison with the non-treated cells (table 1 below).

#### **b.2) Synergy with retinol**

72-hour incubation of the fibroblast with 20 µg/ml of retinol caused a decrease of 42.5% in the cellular proliferation (table 2 below) with respect to the reference without retinol.

In the presence of 20 µg/ml of retinol and of different concentrations of the tested products, simultaneously added to the culture media of the fibroblasts, the cellular proliferation is significantly higher than in the presence of 20 µg/ml of retinol alone. This is a protecting effect that indicates synergy between retinol and the Mixture of oligofucoses-1.

1 µg/ml and 10 µg/ml of the Mixture of oligofucoses-1 increased significantly the cellular proliferation (+24% and +27%, respectively) with respect to the reference (20 µg/ml of retinol alone, table 2 below).

#### **b.3) Synergy with Na ascorbate**

72-hour incubation of the fibroblasts with 375 µg/ml (1.875 mM) of Na ascorbate decreased the incorporation of [<sup>3</sup>H]-timidin, and therefore the cellular proliferation, by about 36% with respect to the control (table 3 below).

In the simultaneous presence of 375 µg/ml of Na ascorbate and of different concentrations of the tested product, the cellular proliferation of the fibroblasts increased significantly with respect to ascorbate alone (table 3 below). The Mixture of oligofucoses-1 is effective both at 1 µg/ml and 10 µg/ml.

#### **b.4) Synergy with ascorbate and retinol**

In the simultaneous presence of 375 µg/ml of Na ascorbate and of 20 µg/ml of retinol, the cellular proliferation of the fibroblasts decreased by about 88% with respect to ascorbate alone (table 4 below).

**TABLE 4: EFFECT OF THE DIFFERENT CONCENTRATIONS OF THE MIXTURE OF OLIGOFUCOSES-1 ON THE CELLULAR PROLIFERATION OF THE FIBROBLASTS OF HUMAN SKIN (PROLIFERATION WITH RESPECT TO THE CONTROL)**

Product	Concentration	Effectiveness with respect to the control	Statistic meaning (p with respect to the control)
Control			
Mixture of oligofucoses-1	1 µg/ml	+4.4	N.S.
Mixture of oligofucoses-1	10 µg/ml	+20.6	*0.019

**TABLE 5: Effect of the different concentrations of the Mixture of oligofucoses-1 on the cytotoxicity of 20 µg/ml of retinol (proliferation with respect to the control and with respect to 20 µg/ml of retinol)**

Treatment	concentration	% 20 µg/ml of retinol	% vs. control	Statistic meaning (p vs. Retinol)	Statistic meaning (P vs control)
Retinol	20 µg/ml		-42.5		0.019
Mixture of oligofucoses-1 + ascorbate 375 µg/ml	1 µg/ml	+ 24.2	-29.3	*0.047	58
Mixture of oligofucoses-1 + ascorbate 375 µg/ml	10 µg/ml	+26.9	-27.1	*0.046	54

**TABLE 6: Effect of the different concentrations of the Mixture of oligofucoses-1 on the cytotoxicity of 375 µg/ml of Na ascorbate (proliferation with respect to the control and with respect to the 375 µg/ml of ascorbate)**

Treatment	concentration	% vs. 375 µg/ml of ascorbate	% vs. control	Statistic meaning (p vs. ascorbate)	Statistic meaning (P vs control)
Na ascorbate	375 µg/ml		-64.4		05
Mixture of oligofucoses-1	1 µg/ml	+96.9	-30.0	**0.003	51

Mixture of oligofucoses-1 + ascorbate 375 µg/ml	10 µg/ml	+80.8	-35.7	*0.015	33
---	----------	-------	-------	--------	----

**TABLE 7: Effect of the different concentrations of the Mixture of oligofucoses-1 on the cytotoxicity of 375 µg/ml of Na ascorbate and of 20 µg/ml of retinol (proliferation with respect to the control and with respect to 375 µg/ml of ascorbate + 20 µg/ml of retinol)**

Treatment	concentration	% vs. Ascorbate + retinol	% vs. control	Statistic meaning (p vs. + retinol + ascorbate)	Statistic meaning (P vs control)
Na ascorbate	375 µg/ml		-64.4		05
Retinol	20 µg/ml		-42.5		19
Na ascorbate + retinol	375 µg/ml + 20 µg/ml		-87.54		03
Mixture of oligofucoses-1 + ascorbate 375 µg/ml	1 µg/ml	+95.2	-75.7	*0.010	04
Mixture of oligofucoses-1 + ascorbate 375 µg/ml	10 µg/ml	+102.8	-74.7	**0.007	04

**5 Example 4: Effect of fucose and of the Mixture of oligofucoses-1 in the presence of sodium ascorbate and/or retinol.**

One studied the influence of fucose and of the Mixture of oligofucoses-1, as prepared in example 1, on the cytotoxic effect of the sodium ascorbate, as well as the influence of these two fucose components on the effect of retinol.

**a) Methodology**

The fibroblasts of mammaplasty of a 45 years old woman, in passage 14, were seeded on 12-well plates at the rate of  $0.5 \cdot 10^5$  cells per

well. The cells are placed in culture for 48 hours in the presence of a DMEM culture medium at 10% of fetal calf serum (SVF), in stove (5% (v/v) CO<sub>2</sub>, 95% (v/v) air) at 37°C.

After rinsing with PBS, they are treated and placed again in culture for 48 hours in the presence of products to be tested and of DMEM without SVF.

The method is based on a specific coloration of collagen by the Sirius red. The cells are directly fixed by the Bouin liquid (1 ml/well) for 1 hour, after exhaustive rinsing with PBS. The fixer is then aspirated and the plates are rinsed with running water by immersion for 15 minutes.

The coloration is carried out under stirring for 1 hour (1 ml/well) and the plates are then rinsed with hydrochloric acid 0.01 N. Then the material is dissolved in 200 µl of sodium hydroxide 0.1N before transferring to the microtiter plates (Nunc). The optical density is measured at 550 nm against sodium hydroxide as a blank.

The counting of the cells is carried out in 4 wells of each plate, and one detaches the cells with trypsin at 0.05%.

One studied the effect of fucose and of the Mixture of oligofucoses-1 (at 10 µg/ml each) in the presence or absence of sodium ascorbate at 500 µg/ml. And then in the presence or absence of retinol (10 µg/ml).

## **b) Results**

### **b.1) Effects of fucose and of the Mixture of oligofucoses-1**

One found a decrease (about 19%) in the amount of collagen synthesized by the fibroblasts in the presence of fucose. This decrease is much greater with concentrations of 1 µg/ml and 10 µg/ml than with 100 µg/ml. The Mixture of oligofucoses-1 does not have a significant effect at 10 µg/ml. These results are represented in Figure 1.

### **b.2) Effects of fucose and of the Mixture of oligofucoses-1 in the presence of sodium ascorbate**

One found an increase in the amount of collagen synthesized by the fibroblasts. Sodium ascorbate causes not only disappearance of the expected inhibition by fucose, but it even induces stimulation of the biosynthe-



sis of collagen. The same stimulating effect of ascorbate is observed in the presence of the Mixture of oligofucoses-1, but the stimulation observed is lower.

5 Sodium ascorbate at 500  $\mu$ g/ml alone activates the synthesis of collagen very little with respect to the effect of 50  $\mu$ g/ml. By adding fucose, one observes an increase in this stimulation, but modest with the Mixture of oligofucoses-1. These results are represented in Figure 2.

**b.3) Effects of fucose and of the Mixture of oligofucoses-1 in the presence of retinol**

10 Retinol alone has an inhibiting effect on the synthesis of collagen. In the presence of fucose, this inhibition is greatly abolished; it is not only abolished but, in addition, a slight stimulation in the presence of the Mixture of oligofucoses-1 occurs. These results are represented in Figure 3.

**c) Conclusion**

15 Free fucose exerts a slight inhibition on the biosynthesis of collagen by the fibroblasts in cultures, whereas the Mixture of oligofucoses-1 does not exert this effect.

20 In the presence of sodium ascorbate at 500  $\mu$ g/ml, the inhibition by fucose disappears and one even observes the existence of greater stimulation in the presence of fucose. In the presence of the Mixture of oligofucoses-1, this stimulation is again found, though somewhat more modest.

Retinol alone at 10  $\mu$ g/ml inhibits the biosynthesis of collagen. This inhibition is completely abolished by adding the Mixture of oligofucoses-1.

25 These results are represented in Figures 1 - 3.

**Example 5: cream against aging**

Component	% (by weight)
Water	q.s.p. 100%
Sodium benzoate	0.2
Disodium EDTA	0.08
Glycerin	2.00
Butylene glycol	4.00

Carbomer and ETD 2020	0.20
Ceteareth-20	1.00
Mineral oil	3.00
Squalane	2.00
Octyl palmitate	6.00
Karité butter ("Shea Butter")	2.50
Cetearyl alcohol	1.00
Rosa AFFF Rubiginosa seed oil	0.20
Decyl oleate	0.50
Octyl methoxycinamate	5.00
Butyl methoxy-dibenzoylmethane	0.50
BHA	0.01
Cyclomethicone	5.00
Cyclomethicone & Dimethiconol	2.00
Dimethicone	2.00
Fragrance (Crematest Feno)	0.09
Fragrance (Chemoderm)	0.09
Triethanolamine	0.30
2-Bromo-2-Nitropropane-1,3-Diol	0.02
Mixture of oligofucoses-1	0.50
Vitamin A	3.50
Vitamin C	1.00

**Exemple 6: cream against aging**

Component	% (by weight)
Water	q.s.p. 100%
Sodium benzoate	0.2
Disodium EDTA	0.08
Glycerin	2.00
Butylene glycol	4.00
Carbomer ETD 2020	0.20
Ceteareth-20	1.00
Mineral oil	3.00
Squalane	2.00

Octyl palmitate	6.00
Karité butter ("Shea butter")	2.50
Cetearyl alcohol	1.00
Rosa AFFF Rubiginosa seed oil	0.20
Decyl oleate	0.50
BHA	0.01
Cyclomethicone	5.00
Cyclomethicone & Dimethiconol	2.00
Dimethicone	2.00
Fragrance (Crematest Feno)	0.09
Fragrance (Chemoderm)	0.09
Triethanolamine	0.30
2-Bromo-2-Nitropropane-1,3-Diol	0.02
Mixture of oligofucoses-1	0.50
Vitamin A	3.50
Vitamin C	1.00

## CLAIMS

1. A cosmetic or pharmaceutical composition characterized in that it comprises at least one vitamin component chosen from the group consisting of vitamin C and its derivatives, vitamin A (or retinol) and its derivatives, and mixtures of these components, in association with at least one fucose component chosen from the group consisting of fucose, polysaccharides and oligosaccharides that contain fucose, and mixtures of these components, as well as at least one cosmetically or pharmaceutically acceptable excipient.
2. A composition according to claim 1, characterized in that the vitamin component is chosen from the group consisting of ascorbic acid, salts and esters thereof, retinol, retinoids other than retinol, and mixtures of the latter.
3. A composition according to claim 1 or 2, characterized in that the vitamin component is chosen from the group consisting of ascorbic acid, sodium ascorbate, ascorbyl phosphate, ascorbyl palmitate, retinol, retinoic acid, retinaldehyde, retinyl palmitate, and mixtures of these components.
4. A composition according to any one of the preceding claims, characterized in that the fucose component is chosen from the group consisting of L-fucose, D-fucose, in the alpha or beta form or a mixture of these alpha and beta forms, fucanes, polysaccharides and oligosaccharides comprising the repetition motif fucose-galactose-galacturonic acid, and mixtures of the latter.
5. A composition according to any one of the preceding claims, characterized in that the fucose component is a mixture of non-sulfated fucose-based oligosaccharides, which comprises oligosaccharides of less than 13 saccharide units that comprise at least one fucose unit in a non-reducing end position, and in that it is susceptible of being obtained by means of a process that comprises at least one step of degradation of a polysaccharide from a microorganism of the gender *Klebiella pneumoniae* subsp. *pneumoniae*.
6. A composition according to claim 5, characterized in that

the mixture of non-sulfated fucose-based oligosaccharides comprises, based on the total weight of the mixture, at least 15% by weight of oligosaccharides of less than 13 saccharide units that comprise at least one fucose unit in a non-reducing end position.

5                   7.       A composition according to claim 5 or 6, characterized in that the mixture of non-sulfated fucose-based oligosaccharides comprises, based on the total weight of the mixture, from 20 to 50% by weight of oligosaccharides of less than 13 saccharide units that comprise at least one fucose unit in a non-reducing end position.

10                  8.       A composition according to any one of claims 5-7, characterized in that the mixture of non-sulfated fucose-based oligosaccharides comprise, on the other hand, based on the total weight of the mixture, from 25 to 45% by weight of oligosaccharides that have from 13 to 24 saccharide units that comprise at least one fucose unit in a non-reducing end position.

15                  9.       A composition according to any one of claims 5-8, characterized in that the mixture of non-sulfated fucose-based oligosaccharides comprise, on the other hand, based on the total weight of the mixture, from 15 to 35% by weight of oligosaccharides of more than 54 saccharide units that comprise at least one fucose unit in a non-reducing end position.

20                  10.      A composition according to any one of claims 5-9, characterized in that the non-sulfated fucose-based oligosaccharides comprise, at least in part, the repetition motif fucose-galactose-galacturonic acid.

25                  11.      A composition according to any one of claims 5-10, characterized in that the mixture of non-sulfated fucose-based oligosaccharides is susceptible of being obtained by means of a process that comprises the steps of:

- a)       causing the microorganism of the gender *Klebsiella pneumoniae subsp. pneumoniae* to grow in an aqueous nutritive medium by aerobic fermentation of an assimilable source of glucide;
- 30       b)       recovering the polysaccharide formed from the fermentation must;
- c)       subjecting the polysaccharide to a moderate hydrolysis;

d) subjecting the hydrolysis product of step c) to an enzymatic hydrolysis; and

e) deactivating the enzyme and then recovering the Mixture of oligosaccharides thus formed.

5           12. A composition according to any one of claims 5-11, characterized in that the microorganism *Klebsiella pneumoniae subsp. pneumoniae* is the microorganism deposited in the National Collection of Cultures of Microorganisms under Number I-1507, or a mutant thereof.

10           13. A composition according to claim 11 or 12, characterized in that the moderate hydrolysis for preparing the mixture of non-sulfated fucose-base oligosaccharides is carried out by means of a treatment chosen from the group consisting of treatments with gamma rays, protolysis treatments and combinations of these treatments.

15           14. A composition according to any one of claims 11-13, characterized in that the enzymatic hydrolysis for preparing the mixture of non-sulfated fucose-based oligosaccharides is carried out with at least one endofucosidase.

          15. A mixture according to claim 14, characterized in that the endofucosidase is Fermizyme HCP.

20           16. A composition according to any one of the preceding claims, characterized in that the concentration of the fucose component ranges from about 0.001 to about 20% by weight, and that the concentration in vitamin component ranges from about 0.001 to about 90% by weight, based on the total weight of the composition.

25           17. A composition according to any one of the preceding claims, characterized in that the weight ratio of vitamin component:fucose component ranges from about 800:1 to about 1:2.

30           18. A composition according to any one of the preceding claims, characterized in that it comprises, on the other hand, a vector in the form of microspheres that contain the vitamin component.

          19. A composition according to any one of the preceding claims, characterized in that it comprises, on the other hand, at least one

cosmetically or pharmaceutically acceptable additive chosen from the group consisting of skin-structuring agents, moistening agents, emollient agents, silicones, sun-protection agents, emulsifiers, thickeners, scavengers, antioxidants, fragrances, preservatives, and mixtures thereof.

5           20.     Use, in a cosmetic or pharmaceutical composition, of at least one vitamin component as defined in any one of claims 1-3, in association with at least one fucose component as defined in any one of claims 1 and 4-15, for reducing the toxic effects of the vitamin component.

10           21.     Use according to claim 20, characterized in that the weight ratio of vitamin component:fucose component ranges from about 800:1 to about 1:2.

          22.     A method of cosmetic treatment of the skin, characterized in that one applies to the skin a cosmetic composition as defined in any one of claims 1-19.

1/3




FIG. 1



2/3




FIG. 2

3/3




FIG. 3

## INTERNATIONAL SEARCH REPORT

In International Application No.

PCI/BR 01/00115

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 7 A61K7/48 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, CHEM ABS Data, MEDLINE, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FR 2 768 623 A (THOREL) 26 March 1999 (1999-03-26) the whole document	1-4, 16, 17, 19-22
X	US 5 686 103 A (REDZINIAK ET AL.) 11 November 1997 (1997-11-11) example 9	1-3, 16, 17, 19-22
X	EP 0 652 012 A (A. NAITO) 10 May 1995 (1995-05-10) examples 9, 10, 14	1
A	DE 198 23 552 A (HENKEL) 2 December 1999 (1999-12-02) claims 1, 5, 10	1-3, 16, 17, 19-22
	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

3 January 2002

Date of mailing of the international search report

11/01/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax (+31-70) 340-3016

Authorized officer

Glikman, J-F

## INTERNATIONAL SEARCH REPORT

Int al Application No

PCI/BK 01/00115

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 610 511 A (SHISEIDO) 17 August 1994 (1994-08-17) claims 1,4,6	1-22
A	DE 198 05 827 A (BEIERSDORF) 19 August 1999 (1999-08-19) the whole document	1-22
A	US 5 780 443 A (MAIER ET AL.) 14 July 1998 (1998-07-14) the whole document	1-22
A	EP 0 667 145 A (L'OREAL) 16 August 1995 (1995-08-16) the whole document	1-22
A	EP 0 818 200 A (L'OREAL) 14 January 1998 (1998-01-14) the whole document	1-22

## INTERNATIONAL SEARCH REPORT

Int'l. Appl. No.  
PCT/BR 01/00115

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
FR 2768623	A	26-03-1999	FR 2768623 A1	26-03-1999
US 5686103	A	11-11-1997	JP 6087900 A US 5332575 A	29-03-1994 26-07-1994
EP 652012	A	10-05-1995	CA 2103399 A1 EP 0652012 A1	19-05-1995 10-05-1995
DE 19823552	A	02-12-1999	DE 19823552 A1 AU 4262599 A WO 9960989 A2 EP 1079795 A2	02-12-1999 13-12-1999 02-12-1999 07-03-2001
EP 610511	A	17-08-1994	JP 3018130 B2 JP 6024956 A JP 2906198 B2 JP 6024957 A JP 2720256 B2 JP 6032728 A EP 0610511 A1 WO 9401083 A1 US 5962000 A US 5686086 A	13-03-2000 01-02-1994 14-06-1999 01-02-1994 04-03-1998 08-02-1994 17-08-1994 20-01-1994 05-10-1999 11-11-1997
DE 19805827	A	19-08-1999	DE 19805827 A1 EP 0937454 A2	19-08-1999 25-08-1999
US 5780443	A	14-07-1998	GB 2282596 A AU 687098 B2 AU 7809694 A BR 9407758 A EP 0722451 A1 JP 9503499 T CZ 9601008 A3 WO 9509862 A1 HR 940646 A1 HU 74456 A2 IL 111152 A ZA 9407775 A	12-04-1995 19-02-1998 01-05-1995 04-03-1997 24-07-1996 08-04-1997 16-10-1996 13-04-1995 30-04-1997 30-12-1996 19-03-2001 17-05-1995
EP 667145	A	16-08-1995	FR 2715565 A1 AT 143256 T CA 2141372 A1 DE 69500048 D1 DE 69500048 T2 EP 0667145 A1 ES 2095174 T3 JP 2705910 B2 JP 8053323 A US 5607921 A	04-08-1995 15-10-1996 01-08-1995 31-10-1996 06-02-1997 16-08-1995 01-02-1997 28-01-1998 27-02-1996 04-03-1997
EP 818200	A	14-01-1998	FR 2750863 A1 CA 2209695 A1 EP 0818200 A1 JP 2993915 B2 JP 10067643 A US 6296856 B1	16-01-1998 10-01-1998 14-01-1998 27-12-1999 10-03-1998 02-10-2001

**THIS PAGE BLANK (USPTO)**

CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 March 2002 (14.03.2002)

PCT

(10) International Publication Number  
**WO 02/019980 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 7/48, 31/70**

F-75013 Paris (FR). **GESZTESI, Jean-Luc** [BR/BR]; Rua General Jardim, 840, 5. andar, São Paulo - SP (BR).

(21) International Application Number: **PCT/BR01/00115**

(22) International Filing Date:

11 September 2001 (11.09.2001)

(74) Agent: **DANNEMANN, SIEMSEN, BIGLER & IPANEMA MOREIRA**; Caixa Postal 2142, Rua Marques de Olinda, 70, Botafogo, CEP-22251-040 Rio de Janeiro, RJ (BR).

(25) Filing Language:

English

(81) Designated States (*national*): CA, JP, MX, US.

(26) Publication Language:

English

(84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

(30) Priority Data:

00/11546 11 September 2000 (11.09.2000) FR  
PI 0100957-5 13 March 2001 (13.03.2001) BR

Published:

— with international search report

(71) Applicant (*for all designated States except US*): **INDÚSTRIA E COMÉRCIO DE COSMÉTICOS NATURA LTDA.** [BR/BR]; Rodovia Anhanguera s/n - Km 30,5, CEP-0007750-000 Cajamar, SP (BR).

(48) Date of publication of this corrected version:

16 October 2003

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **ROBERT, Ladislav** [FR/FR]; 7, rue Jean-Baptiste Lully, F-94440 Santeny (FR). **ROBERT, Alexander, Michel** [FR/FR]; 41, rue François Couperin, F-94440 Santeny (FR). **ROBERT, Catherine, Sylvie** [FR/FR]; 10 Villa D'Este, Tour Atlas, ap. 805,

(15) Information about Correction:

see PCT Gazette No. 42/2003 of 16 October 2003, Section II

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **COMPOSITION OF VITAMIN C AND/OR VITAMIN A**

(57) Abstract: The present invention relates to a new cosmetic or pharmaceutical composition characterized in that it comprises at least one vitamin component chosen from the group consisting of vitamin C and its derivatives, vitamin A (or retinol) and its derivatives, and mixtures of these components, in association with at least one fucose component chosen from the group consisting of fucose, polysaccharides and oligosaccharides that contain fucose, consisting of fucose, polysaccharides and oligosaccharides that contain fucose, and mixtures of these components, as well as at least one acceptable excipient. This composition enables one to reduce significantly, by means of a real synergy effect, the toxic effect of the vitamin component and, therefore, to use in the composition contents of the vitamin component higher or equal to the contents of the products that already exist on the market, without any risk for the user.

WO 02/019980 A1

**THIS PAGE BLANK (USPTO)**